Stryker stock faces pressure after 2026 outlook cut

Published on 11/10/2026 at 16:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stryker stock remains under pressure after management lowered its 2026 outlook. Stronger adjusted margins provide some support for investors.

Outlook cut raises execution pressure

Stryker lowered its full-year 2026 organic sales and adjusted earnings outlook after third-quarter performance fell short of management expectations.
Adjusted margin expansion partly offset weaker reported earnings and a goodwill impairment.
Procedure volumes, Orthopaedics execution and fourth-quarter performance are the next key investor tests.

Stryker Corp., US8636671013, Illustration mit AI erstellt.

Stryker lowered its full-year 2026 outlook after third-quarter performance fell short of management expectations on October 29. The medical-device maker still delivered sales growth and stronger adjusted profitability, according to the Stryker release published by GlobeNewswire.

Growth remained uneven

Third-quarter sales rose 7.7 percent year over year to 6.52 billion US dollars, while organic sales increased at the same rate. MedSurg and Neurotechnology sales advanced 9.2 percent to 3.7 billion US dollars, outpacing Orthopaedics, where sales grew 5.7 percent to 2.9 billion US dollars.

Reported net earnings fell 12.3 percent to 753 million US dollars, and diluted earnings per share declined 11.7 percent to 1.96 US dollars. The quarter included a 293 million US dollar goodwill impairment. Adjusted net earnings increased 10.1 percent to 1.4 billion US dollars, adjusted diluted earnings per share rose 10.3 percent to 3.52 US dollars, and adjusted operating margin widened 60 basis points to 26.2 percent.

Guidance reset raises pressure

Stryker now expects full-year 2026 organic sales growth of 6.5 to 7.0 percent, below the previous range of 8.3 to 9.3 percent. Adjusted diluted earnings per share are forecast at 14.80 to 14.90 US dollars, compared with the former range of 14.95 to 15.10 US dollars.

Management said it expects solid fourth-quarter performance and momentum entering 2027. For investors, the lower targets increase the importance of procedure volumes, Orthopaedics execution and the company's ability to preserve margin expansion.

Share price and investor focus

Stryker stock traded at 284.95 euros on Lang & Schwarz at 16:32 CET on Tuesday, November 10, 2026, 2.06 percent below the Xetra close of Monday, November 9. This daily comparison puts the latest European trading indication below the prior Xetra session.